Adjuvant abemaciclib with endocrine therapy (ET) improves clinical outcomes in patients with high-risk node-positive early-stage hormone receptor-positive/HER2-negative (HR-positive/HER2-negative) breast cancer (BC), based on the monarchE trial. Patients may experience tolerability issues at the standard abemaciclib dose [150 mg twice daily (b.i.d.)], potentially leading to early treatment discontinuation, particularly within the initial weeks of therapy. TRADE is a prospective, single-arm, phase…
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer☆
Annals of Oncology | | E.L. Mayer, D. Trapani, S.-E. Kim, M. Faggen, N. Sinclair, P. Sanz-Altamira, C. Battelli, S. Berwick, S. Lo, J. Acevedo, S. Sinclair, A. Malcolm, L. Varella, S. Sammons, S. Schumer, P.D. Poorvu, E. Wallace, E. Pasternak, N. Tayob, S.M. Tolaney
Topics: breast-cancer, blood-cancer, clinical-trials, research